Urogen Pharma Ltd. (URGN) Stock Price & Analysis
Urogen Pharma Ltd. (URGN) rose 3.41% to USD 28.18 as of June 10, 2026 at 08:32 UTC, according to Nexqual real-time market data.
URGN last closed at USD 27.25; the session ranged USD 26.6–28.46 on volume of 807,973 shares. Market capitalization is $1.37B, with a 52-week range of USD 6.92–32.37 (NGM). Source: Nexqual, June 10, 2026 at 08:32 UTC.
Key Statistics (as of June 10, 2026 at 08:32 UTC)
| Price | USD 28.18 |
|---|---|
| Change | ▲ 3.41% (up) |
| Previous Close | USD 27.25 |
| Open | USD 27.98 |
| Day Range | USD 26.6 – 28.46 |
| 52-Week Range | USD 6.92 – 32.37 |
| Volume | 807,973 shares |
| Market Cap | $1.37B |
| Exchange | NGM |
Technical Analysis (URGN)
Nexqual's technical model rates URGN "NEUTRAL" based on 3 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 08:32 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.79 (neutral) |
| vs SMA50 | Above (USD 24.81) |
| MACD | 0.47 (positive) |
Analyst Ratings (URGN)
Wall Street analysts rate URGN "Strong Buy" based on 8 analysts, with a mean price target of USD 36.88 (range USD 18–45), per Nexqual as of June 10, 2026 at 08:32 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 36.88 |
| High Target | USD 45 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 6 / 1 / 0 |
Earnings (URGN)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.3 |
| Revenue Estimate | $61.59M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.47 vs est -0.48 ▲ beat |
| 2025-12-31 | USD -0.53 vs est -0.51 ▼ miss |
| 2025-09-30 | USD -0.69 vs est -0.68 ▼ miss |
| 2025-06-30 | USD -1.05 vs est -0.83 ▼ miss |
Source: Nexqual, June 10, 2026 at 08:32 UTC.
Financials & Fundamentals (URGN)
| Total Revenue | $140.49M |
|---|---|
| Revenue Growth (YoY) | +151.60% |
| Gross Margin | +89.85% |
| Operating Margin | -39.76% |
| Profit Margin | -94.83% |
| Current Ratio | 4.69 |
| Total Cash | $140.27M |
| Total Debt | $197.09M |
| Free Cash Flow | $-109.28M |
Source: Nexqual, June 10, 2026 at 08:32 UTC.
Financial Health Score (URGN)
Nexqual rates Urogen Pharma Ltd.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 08:32 UTC.
| Growth | Strong — Revenue +21% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 90%, operating -40% |
| Balance Sheet | Mixed — $140M cash vs $197M debt |
| Cash Flow | Weak — FCF negative: -$109M, burning cash |
| Efficiency | Mixed — No data |
Ownership (URGN)
| Insider Ownership | +3.65% |
|---|---|
| Institutional Ownership | +100.59% |
| Shares Outstanding | 48.72M |
| Float | 43.18M |
| Short % of Float | +14.49% |
Source: Nexqual, June 10, 2026 at 08:32 UTC.
Leadership (URGN)
Urogen Pharma Ltd. is led by Elizabeth A. Barrett (age 63), President, CEO & Director, per Nexqual as of June 10, 2026 at 08:32 UTC.
| President, CEO & Director | Elizabeth A. Barrett (age 63) |
|---|---|
| Chief Financial Officer | Christopher Degnan (age 45) |
| Senior Director of Investor Relations | Vincent I. Perrone |
| Senior Vice President of Human Resources | Alison Hardgrove |
| Executive Vice President of Research & Development and Technical Operations | Marina Konorty |
Major Backers & Investors (URGN)
Notable institutional backers of Urogen Pharma Ltd. include RTW Investments LP, Toronto Dominion Bank, Morgan Stanley, according to Nexqual as of June 10, 2026 at 08:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RTW Investments LP | 9.33% |
| Toronto Dominion Bank | 5.37% |
| Morgan Stanley | 5.25% |
| American Century Companies Inc | 5.16% |
| Kynam Capital Management, LP | 4.61% |
| Jefferies Financial Group Inc. | 4.51% |
| Paradigm Biocapital Advisors LP | 3.5% |
| Acorn Capital Advisors, LLC | 3.43% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.94% |
Source: Nexqual, June 10, 2026 at 08:32 UTC.
From Urogen Pharma Ltd.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- Serious adverse reactions occurred in 12% of patients who received  Zusduri , including, urinary retention (0.8%) and urethral stenosis (0.4%).   As a post-marketing commitment, we have agreed with the FDA to complete the ongoing ENVISION trial to further characterize the clinical benefit of  Zusduri  for the treatment of adult patients with recurrent low-grade intermediate risk NMIBC.
- Furthermore, we believe our proprietary formulation technology has broad applications and may allow us to develop additional product candidates for indications within and beyond the urinary tract.   9 Table of Contents   Potential ability to develop additional minimally invasive, drug therapies for uro-oncology .
- Furthermore, Jelmyto has received Orphan Drug Designation from the FDA for the treatment of low-grade UTUC, which provides seven years of regulatory exclusivity following FDA approval.   Leverageable proprietary formulation technology.
- We have developed  RTGel  reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs.
Partnerships
- In November 2025, we provided notice to terminate the license agreement with Agenus in connection with our decision to discontinue development of UGN-301.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ANAB | AnaptysBio, Inc. | USD 51.63 | ▲ 2.5% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.86 | ▲ 1.69% |
| KALV | KalVista Pharmaceuticals, Inc. | USD 26.99 | ▲ 0.15% |
| PHAT | Phathom Pharmaceuticals, Inc. | USD 9.82 | ▼ 3.06% |
| REPL | Replimune Group, Inc. | USD 9.24 | ▼ 2.43% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:32 UTC. This page is informational and not investment advice.